Bukwang Pharm (003000) - Total Assets
Based on the latest financial reports, Bukwang Pharm (003000) holds total assets worth ₩472.99 Billion KRW (≈ $320.54 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Bukwang Pharm for net asset value and shareholders' equity analysis.
Bukwang Pharm - Total Assets Trend (2007–2024)
This chart illustrates how Bukwang Pharm's total assets have evolved over time, based on quarterly financial data.
Bukwang Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Bukwang Pharm's total assets of ₩472.99 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 24.1% |
| Accounts Receivable | ₩23.56 Billion | 6.3% |
| Inventory | ₩41.67 Billion | 11.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.87 Billion | 1.6% |
| Goodwill | ₩406.62 Million | 0.1% |
Asset Composition Trend (2007–2024)
This chart illustrates how Bukwang Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 003000 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bukwang Pharm's current assets represent 54.6% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 24.1% of total assets in 2024, up from 14.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 11.2% of total assets.
Bukwang Pharm Competitors by Total Assets
Key competitors of Bukwang Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Bukwang Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 6.84 | 4.06 |
| Quick Ratio | 3.81 | 5.22 | 3.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩239.47 Billion | ₩166.58 Billion | ₩187.00 Billion |
Bukwang Pharm - Advanced Valuation Insights
This section examines the relationship between Bukwang Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | ₩373.18 Billion |
| Market Capitalization | $422.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bukwang Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bukwang Pharm's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bukwang Pharm (2007–2024)
The table below shows the annual total assets of Bukwang Pharm from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩373.18 Billion ≈ $252.90 Million |
-13.02% |
| 2023-12-31 | ₩429.02 Billion ≈ $290.74 Million |
+7.01% |
| 2022-12-31 | ₩400.93 Billion ≈ $271.70 Million |
+0.88% |
| 2021-12-31 | ₩397.42 Billion ≈ $269.32 Million |
-0.89% |
| 2020-12-31 | ₩400.97 Billion ≈ $271.73 Million |
+3.20% |
| 2019-12-31 | ₩388.53 Billion ≈ $263.30 Million |
-21.29% |
| 2018-12-31 | ₩493.62 Billion ≈ $334.52 Million |
+108.96% |
| 2017-12-31 | ₩236.23 Billion ≈ $160.09 Million |
-0.59% |
| 2016-12-31 | ₩237.63 Billion ≈ $161.04 Million |
-6.32% |
| 2015-12-31 | ₩253.66 Billion ≈ $171.90 Million |
+7.11% |
| 2014-12-31 | ₩236.82 Billion ≈ $160.49 Million |
+3.77% |
| 2013-12-31 | ₩228.21 Billion ≈ $154.66 Million |
-1.01% |
| 2008-12-31 | ₩230.55 Billion ≈ $156.24 Million |
+7.22% |
| 2007-12-31 | ₩215.02 Billion ≈ $145.71 Million |
-- |
About Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more